Sarepta Announces Date for SRP-9001 FDA Advisory Committee Meeting: Make Your Voice Heard on May 12th
Today Sarepta shared that the FDA has announced that the planned Advisory Committee meeting for SRP-9001 (delandistrogene moxeparvovec), Sarepta’s investigational gene therapy for Duchenne muscular dystrophy, will be held on May 12, 2023. The event…Learn More